Reference Materials and Resources
Reference Materials and Resources

Table of Contents

CDC Guidelines, March 2016.................................................................1
CDC Guidelines Checklist, March 2016..................................................3
General Safety Information for Providers ..............................................5
Patient Education and Counseling Tips .................................................9
FDA Patient Counseling Document .....................................................15
Safe Disposal Information (FDA and DEA) ...........................................17
Article about Efficacy of SCOPE of Pain Education ..............................23
NEJM Perspectives Article about Safe Opioid Prescribing Education ........35
Bibliography.........................................................................................39
**Recommendations and Reports**

**BOX 1. CDC recommendations for prescribing opioids for chronic pain outside of active cancer, palliative, and end-of-life care**

**Determining When to Initiate or Continue Opioids for Chronic Pain**

1. Nonpharmacologic therapy and nonopioid pharmacologic therapy are preferred for chronic pain. Clinicians should consider opioid therapy only if expected benefits for both pain and function are anticipated to outweigh risks to the patient. If opioids are used, they should be combined with nonpharmacologic therapy and nonopioid pharmacologic therapy, as appropriate.

2. Before starting opioid therapy for chronic pain, clinicians should establish treatment goals with all patients, including realistic goals for pain and function, and should consider how therapy will be discontinued if benefits do not outweigh risks. Clinicians should continue opioid therapy only if there is clinically meaningful improvement in pain and function that outweighs risks to patient safety.

3. Before starting and periodically during opioid therapy, clinicians should discuss with patients known risks and realistic benefits of opioid therapy and patient and clinician responsibilities for managing therapy.

**Opioid Selection, Dosage, Duration, Follow-Up, and Discontinuation**

4. When starting opioid therapy for chronic pain, clinicians should prescribe immediate-release opioids instead of extended-release/long-acting (ER/LA) opioids.

5. When opioids are started, clinicians should prescribe the lowest effective dosage. Clinicians should use caution when prescribing opioids at any dosage, should carefully reassess evidence of individual benefits and risks when increasing dosage to ≥50 morphine milligram equivalents (MME)/day, and should avoid increasing dosage to ≥90 MME/day or carefully justify a decision to titrate dosage to ≥90 MME/day.

6. Long-term opioid use often begins with treatment of acute pain. When opioids are used for acute pain, clinicians should prescribe the lowest effective dose of immediate-release opioids and should prescribe no greater quantity than needed for the expected duration of pain severe enough to require opioids. Three days or less will often be sufficient; more than seven days will rarely be needed.

7. Clinicians should evaluate benefits and harms with patients within 1 to 4 weeks of starting opioid therapy for chronic pain or of dose escalation. Clinicians should evaluate benefits and harms of continued therapy with patients every 3 months or more frequently. If benefits do not outweigh harms of continued opioid therapy, clinicians should optimize other therapies and work with patients to taper opioids to lower dosages or to taper and discontinue opioids.

**Assessing Risk and Addressing Harms of Opioid Use**

8. Before starting and periodically during continuation of opioid therapy, clinicians should evaluate risk factors for opioid-related harms. Clinicians should incorporate into the management plan strategies to mitigate risk, including considering offering naloxone when factors that increase risk for opioid overdose, such as history of overdose, history of substance use disorder, higher opioid dosages (≥50 MME/day), or concurrent benzodiazepine use, are present.

9. Clinicians should review the patient's history of controlled substance prescriptions using state prescription drug monitoring program (PDMP) data to determine whether the patient is receiving opioid dosages or dangerous combinations that put him or her at high risk for overdose. Clinicians should review PDMP data when starting opioid therapy for chronic pain and periodically during opioid therapy for chronic pain, ranging from every prescription to every 3 months.

10. When prescribing opioids for chronic pain, clinicians should use urine drug testing before starting opioid therapy and consider urine drug testing at least annually to assess for prescribed medications as well as other controlled prescription drugs and illicit drugs.

11. Clinicians should avoid prescribing opioid pain medication and benzodiazepines concurrently whenever possible.

12. Clinicians should offer or arrange evidence-based treatment (usually medication-assisted treatment with buprenorphine or methadone in combination with behavioral therapies) for patients with opioid use disorder.

*All recommendations are category A (apply to all patients outside of active cancer treatment, palliative care, and end-of-life care) except recommendation 10 (designated category B, with individual decision making required); see full guideline for evidence ratings.*
Checklist for prescribing opioids for chronic pain

For primary care providers treating adults (18+) with chronic pain ≥ 3 months, excluding cancer, palliative, and end-of-life care

**CHECKLIST**

**When CONSIDERING long-term opioid therapy**

- Set realistic goals for pain and function based on diagnosis (eg, walk around the block).
- Check that non-opioid therapies tried and optimized.
- Discuss benefits and risks (eg, addiction, overdose) with patient.
- Evaluate risk of harm or misuse:
  - Discuss risk factors with patient.
  - Check prescription drug monitoring program (PDMP) data.
  - Check urine drug screen.
- Set criteria for stopping or continuing opioids.
- Assess baseline pain and function (eg, PEG scale).
- Schedule initial reassessment within 1–4 weeks.
- Prescribe short-acting opioids using lowest dosage on product labeling; match duration to scheduled reassessment.

**If RENEWING without patient visit**

- Check that return visit is scheduled ≤ 3 months from last visit.

**When REASSESSING at return visit**

*Continue opioids only after confirming clinically meaningful improvements in pain and function without significant risks or harm.*

- Assess pain and function (eg, PEG); compare results to baseline.
- Evaluate risk of harm or misuse:
  - Observe patient for signs of over-sedation or overdose risk.
    - If yes: Taper dose.
  - Check PDMP.
  - Check for opioid use disorder if indicated (eg, difficulty controlling use).
    - If yes: Refer for treatment.
- Check that non-opioid therapies optimized.
- Determine whether to continue, adjust, taper, or stop opioids.
- Calculate opioid dosage morphine milligram equivalent (MME).
  - If ≥ 50 MME/day total (≥ 50 mg hydrocodone; ≥ 33 mg oxycodone), increase frequency of follow-up; consider offering naloxone.
  - Avoid ≥ 90 MME/day total (≥ 90 mg hydrocodone; ≥ 60 mg oxycodone), or carefully justify; consider specialist referral.
- Schedule reassessment at regular intervals (≤ 3 months).

**REFERENCE**

**EVIDENCE ABOUT OPIOID THERAPY**

- Benefits of long-term opioid therapy for chronic pain not well supported by evidence.
- Short-term benefits small to moderate for pain; inconsistent for function.
- Insufficient evidence for long-term benefits in low back pain, headache, and fibromyalgia.

**NON-OPIOID THERAPIES**

Use alone or combined with opioids, as indicated:

- Non-opioid medications (eg, NSAIDs, TCAs, SNRIs, anti-convulsants).
- Physical treatments (eg, exercise therapy, weight loss).
- Behavioral treatment (eg, CBT).
- Procedures (eg, intra-articular corticosteroids).

**EVALUATING RISK OF HARM OR MISUSE**

Known risk factors include:

- Illegal drug use; prescription drug use for nonmedical reasons.
- History of substance use disorder or overdose.
- Mental health conditions (eg, depression, anxiety).
- Sleep-disordered breathing.
- Concurrent benzodiazepine use.

**Urine drug testing**: Check to confirm presence of prescribed substances and for undisclosed prescription drug or illicit substance use.

**Prescription drug monitoring program (PDMP)**:

Check for opioids or benzodiazepines from other sources.

**ASSESSING PAIN & FUNCTION USING PEG SCALE**

PEG score = average 3 individual question scores (30% improvement from baseline is clinically meaningful)

- **Q1**: What number from 0–10 best describes your pain in the past week?
  - 0 = “no pain”, 10 = “worst you can imagine”
- **Q2**: What number from 0–10 describes how, during the past week, pain has interfered with your enjoyment of life?
  - 0 = “not at all”, 10 = “complete interference”
- **Q3**: What number from 0–10 describes how, during the past week, pain has interfered with your general activity?
  - 0 = “not at all”, 10 = “complete interference”

TO LEARN MORE

[www.cdc.gov/drugoverdose/prescribing/guideline.html](http://www.cdc.gov/drugoverdose/prescribing/guideline.html)
Extended Release/Long-Acting Opioids

General Drug Safety Information

This document is provided as a SUMMARY only of side effects and potential drug-drug interactions, for your reference as you prescribe ER/LA Opioids. Please consult the following for more information:
- [https://dailymed.nlm.nih.gov/dailymed/](https://dailymed.nlm.nih.gov/dailymed/) for DETAILED product-specific information, including side effects and contraindications

ER/LA opioid analgesic products are scheduled under the Controlled Substances Act and can be misused and abused.

SIDE EFFECTS:
- MOST COMMON: Constipation. This should be anticipated, and discussed with your patients.
- MOST SERIOUS: Respiratory depression (RD). Patients should be monitored for respiratory depression. You should explain the relative risks and describe appropriate measure to take (including calling 911), as RD can be immediately life-threatening.

DRUG INTERACTIONS AND COMPLICATIONS:
- CNS depressants. ER/LA Opioids are also CNS depressants; combining them with any of the substances below can increase the sedation and respiratory depression effected by the opioids.
  - Alcohol
  - Sedatives
  - Hypnotics
  - Tranquilizers
  - Tricyclic antidepressants
- “Dose Dumping”. Exposure to alcohol may cause rapid release of some ER opioid formulations. Alcohol exposure may cause some opioid drug levels to increase, even without dose dumping.
- MAOIs. Use of opioids with MAOIs may result in possible increase in respiratory depression. Use of certain opioids with MAOIs may cause serotonin syndrome (interference with serotonin metabolism, resulting in neuromuscular, autonomic, and behavioral changes due to increased CNS serotonin activity)
- Diuretics. Opioids can reduce the efficacy of diuretics by inducing the release of antiuretic hormone.
- QTc interval. Methadone and buprenorphine can prolong the QTc interval, increasing the risk of sudden cardiac death.
- MRIs. Patients should NOT wear transdermal fentanyl during MRIs (because of the metal foil backing on the patch).

TOLERANCE TO SEDATING AND RESPIRATORY-DEPRESSANT EFFECTS:
- Patients MUST be opioid tolerant before using any strength of
  - Transdermal fentanyl
  - ER hydromorphone
- Other ER/LA opioids require patients to be opioid tolerant before using
  - Certain strengths
  - Certain daily doses
Selected Important Safety Information

ABUSE POTENTIAL AND RISK OF LIFE-THREATENING RESPIRATORY DEPRESSION

The branded and generic drug products subject to this REMS include all:

- extended-release, oral dosage forms containing
  - hydromorphone,
  - morphine,
  - oxycodone,
  - oxymorphone, or
  - tapentadol;
- fentanyl and buprenorphine-containing transdermal delivery systems; and
- methadone tablets and solutions that are indicated for use as analgesics.

These drug products will be collectively referred to as Extended-Release and Long-Acting (ER/LA) prescription opioid analgesics.

ER/LA prescription opioid analgesics are opioid agonists and Schedule II or, Schedule III, as is the case with transdermal buprenorphine, controlled substances with abuse liabilities similar to other opioid agonists. Schedule II and Schedule III opioid substances have high potential for abuse and risk of fatal overdose due to respiratory depression.

ER/LA opioid analgesics can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing ER/LA opioid analgesics in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse, or diversion.

Persons at increased risk for opioid abuse include those with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression). Patients should be assessed for their clinical risks for opioid abuse or addiction prior to being prescribed opioids. All patients receiving opioids should be routinely monitored for signs of misuse, abuse and addiction.

ER/LA opioid analgesics containing buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone, oxymorphone, and tapentadol are indicated for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. **ER/LA opioid analgesics are not indicated for acute pain. Additionally, ER hydromorphone and transdermal fentanyl products are indicated for use in opioid-tolerant patients only.**

For some of the other ER/LA opioid analgesics, certain dosage strengths or certain doses are for use in opioid-tolerant patients only. Consult the individual Full Prescribing Information for dosing instructions for patients who are not opioid tolerant. ER/LA opioid analgesics are not intended for acute pain, pain that is mild or not expected to persist for an extended period of time, or for use on an as-needed basis.

Patients considered opioid tolerant are those who are taking at least 60 mg oral morphine/day, 25 mcg transdermal fentanyl/hour, 30 mg oral oxycodone/day, 8 mg oral hydromorphone/day, 25 mg oral oxymorphone/day, or an equianalgesic dose of another opioid for one week or longer.
ER/LA opioid analgesic formulations have product specific dosage and administration instructions. Refer to the individual Full Prescribing Information for specific doses and dosing recommendations.

ER/LA oral dosage forms must be swallowed whole and must not be cut, broken, chewed, crushed, or dissolved. Taking cut, broken, chewed, crushed or dissolved oral dosage forms leads to rapid release and absorption of a potentially fatal dose of the opioid agonist. For patients who have difficulty swallowing their medication whole, certain oral products may be opened and sprinkled on applesauce—refer to the product-specific Full Prescribing Information.

Transdermal dosage forms must not be cut, damaged, chewed, swallowed or used in ways other than indicated since this may cause choking or overdose resulting in death. Avoid direct external heat sources to transdermal application site and surrounding area.

ER/LA opioid analgesics are contraindicated in patients with a known hypersensitivity to any of the components of ER/LA opioid analgesics, including the respective active ingredients, or in any situation where opioids are contraindicated; in patients who have significant respiratory depression; in patients who have acute or severe bronchial asthma; or in patients who have or are suspected of having paralytic ileus. Additionally, ER hydromorphone and transdermal fentanyl products are contraindicated for use in opioid non-tolerant patients. These contraindications are not all-inclusive of those for each individual ER/LA opioid analgesic; therefore, the Full Prescribing Information for the individual ER/LA opioid analgesics must be consulted.

The concomitant use of ER/LA opioid analgesics containing buprenorphine, fentanyl, methadone, or oxycodone with cytochrome P450 3A4 inhibitors may result in increased opioid plasma concentrations and may cause potentially fatal respiratory depression.

**Adverse Reactions**

Serious adverse reactions of ER/LA opioid analgesics include life threatening respiratory depression, apnea, respiratory arrest, circulatory depression, hypotension, and death.

Accidental exposure of ER/LA opioids, especially in children, can result in death.

With methadone, cases of QT interval prolongation and serious arrhythmia (torsades de pointes) have been observed during treatment. Most cases involve patients being treated for pain with large, multiple daily doses of methadone, although cases have been reported in patients receiving doses commonly used for maintenance treatment of opioid addiction. A positive-controlled study of the effects of transdermal buprenorphine on the QTc interval in healthy subjects demonstrated no clinically meaningful effect at a transdermal buprenorphine dose of 10 mcg/hour; however, a transdermal buprenorphine dose of 40 mcg/hour (given as two 20 mcg/hour transdermal buprenorphine systems) was observed to prolong the QTc interval.

The most common adverse reactions of ER/LA opioid analgesics include constipation, nausea, somnolence, dizziness, vomiting, pruritus, headache, dry mouth, asthenia, and sweating. Additionally, the following have been reported with
transdermal buprenorphine and fentanyl products: application site pruritus, application site erythema, and application site rash. Refer to the individual Full Prescribing Information for all product-specific adverse reactions.

**Adverse Event Reporting**

Please report all suspected adverse reactions associated with the use of the specific ER/LA opioid analgesic to the appropriate company. You may also report adverse events directly to the FDA's MedWatch Reporting System:

- by calling 1-800-FDA-1088 (1-800-332-1088),
- online at [https://www.accessdata.fda.gov/scripts/medwatch/medwatch-online.htm](https://www.accessdata.fda.gov/scripts/medwatch/medwatch-online.htm) or

**Patient Counseling Document and Medication Guide**

The Patient Counseling Document (PCD) on Extended-Release/Long-Acting Opioids is a tool unique to this REMS designed to facilitate important discussions with your patients for whom you select an ER/LA opioid analgesic. The PCD should be provided to the patient and/or their caregiver at the time of prescribing. It contains important safety information about the drug products subject to this REMS and includes space for you to write additional information to help your patients use their ER/LA opioid analgesic safely.

Patients and their caregivers should be counseled on: the importance of taking these medicines exactly as you prescribe them, the need to store ER/LA opioid analgesics safely and securely—out of the reach of children, pets, and household acquaintances to avoid risks from unintended exposure, the importance of not sharing these medications, even if someone has the same symptoms as the patient, and the proper methods of disposal of unneeded ER/LA opioid analgesics.

It is important that you encourage your patients to read the relevant Medication Guide when they pick up their prescription from the pharmacy. The Medication Guide provides important information on the safe and effective use of the specific ER/LA opioid analgesic prescribed.
Opioid Analgesics
Basic Patient Counseling Talking Points

Your patients need some basic information about the safer use of opioid analgesics. This information provided here is an outline of those points which should be communicated clearly to patients, whether they are just starting opioid therapy or managing their pain long-term with chronic opioid therapy. This document can be printed and kept handy in your office for easy reference. Please also refer to the FDA Patient Counseling Guide.

1. **PRINT** and distribute product-specific information; confirm that patients and/or caregivers will read it (available here: [https://dailymed.nlm.nih.gov/dailymed/](https://dailymed.nlm.nih.gov/dailymed/))

2. **EXPLAIN** details of how to take the medication
   a. Specific dosage
   b. When to take it
   c. How many per day (or within a certain number of hours)
   d. How to take if patient cannot swallow pills/capsules (refer to product-specific information)
   e. Special handling requirements for patch (patient should be aware that external heat, fever, and exertion can increase absorption, leading to overdose)

3. **EXPLAIN** importance of adherence to regimen
   a. How to handle missed doses
   b. Not to increase dosage or decrease interval OR abruptly stop taking opioids
   c. When to call PCP (if pain is not controlled)

4. **WARN** patients of what NOT TO DO
   a. Do NOT break, chew or crush oral medications
   b. Do NOT cut or tear patches prior to use
   c. Do NOT share opioids with others
   d. Do NOT sell or give away opioids (against the law)

5. **WARN** patients of adverse effects/consequences of opioids
   a. Describe common side effects (refer to specific medication information)
   b. Remind patients to call PCP regarding side effects
   c. Describe possibilities of severe side effects (including death)
   d. Describe overdose risks (and risk of death from overdose)

6. **INSTRUCT** patients on safe storage and disposal
   a. Lock boxes – safe from children, family members, visitors, pets
   b. Disposal (refer to product-specific information)
      i. Mix with coffee grounds and put in trash
      ii. Flush down the toilet
      iii. Find national, state, or local “take-back days” (refer to [https://takebackday.dea.gov](https://takebackday.dea.gov))
Misuse of Opioid Medication

About 100 million Americans have chronic pain and some may be treated with opioid medications. Opioid medications include codeine, morphine, oxycodone, and fentanyl, among others. These medications can help some people and harm others. In the United States, opioid medications are the second most common drug abused after marijuana.

Opioid medication misuse is defined as use of an opioid medication different than the way in which it was prescribed (for example, in higher doses) or for reasons other than why it was prescribed (for example, to get high).

An article published in the March 6, 2013, issue of *JAMA* discussed opioid misuse.

**RISK FACTORS FOR OPIOID MEDICATION MISUSE**

- Younger age (<45 years)
- Personal history of substance abuse, mental illness, or legal problems
- Family history of substance abuse

**WHAT YOU SHOULD KNOW ABOUT USING OPIOIDS**

Not all chronic pain gets better with use of opioids. Opioids can cause side effects, addiction, overdose, and death. Before prescribing opioids, your doctor will need to teach you about how opioid medications can help you and how they can harm you. This may include having you sign an agreement form.

Using opioids safely includes

- Not chewing or crushing the medication
- Not increasing the dose on your own
- Not sharing the medication with others
- Keeping the medication safe from others
- Throwing out extra opioid medications by mixing them with used coffee grounds or cat litter

The risk of harm from opioids is highest

- When the opioid medication is started
- When the dose is increased
- With a high dose (for example, more than 100 mg of morphine)
- When also taking sleep or anxiety medications or using alcohol

**MONITORING FOR BENEFIT AND HARM**

When you first begin taking an opioid medication, your doctor should see you often. To know if the opioids are helping you, your doctor will ask you if your pain and function are getting better. Your doctor will also look for evidence that the opioids are not helping, are being misused, or are harming you by causing side effects that are unsafe or that stop you from performing your normal daily activities. To check for opioid medication misuse, your doctor may use urine drug tests, pill counts, and official websites that show your prescription history. Urine drug tests are helpful to make sure the opioid is being taken and to see if there is any other drug abuse. Pill counts are helpful to see if you are taking the medication as prescribed. Official websites are helpful to show whether other doctors are prescribing medications to you. If your doctor is worried about opioid medication misuse (for example, if no opioid is found in the urine or an incorrect number of pills remain in your pill bottle), your doctor may decide that the opioid medication is too dangerous for you and will need to be stopped. If your body is physically dependent on the opioid, your doctor may decrease the opioid dose slowly so that you do not get sick from withdrawal.

Daniel P. Alford, MD, MPH, Writer
Edward H. Livingston, MD, Editor
What Should I Know About Opioids?

What Are Opioids?
Opioids are a group of substances derived from the plant-based chemical opium. Today many opioids are artificially created to have stronger or longer-lasting effects. Opioids include both prescription medications and illicit drugs. Examples include morphine, hydrocodone, oxycodone, codeine, hydromorphone, tramadol, fentanyl, and heroin. Opioids are addictive. Over time people’s bodies require more and more opioid to achieve the same effects. Withdrawing symptoms can appear if opioids are not taken regularly. Opioids can cause death by slowing breathing and causing extreme sedation.

Is My Opioid Use a Problem?
• When a person’s pattern of opioid use leads to life problems, poor function, or physical harm, they may have opioid use disorder—the medical term for addiction to opioids.
• Recognizing the signs of opioid use disorder in yourself or a loved one can save a life. They include: Craving opioids; using more opioids than intended; problems at work or in relationships owing to opioid use; use in potentially dangerous situations, such as driving; increasing time spent using or searching for opioids; continued use after a bad reaction, overdose, or other harm; the presence of withdrawal symptoms when opioids are not taken.
• These symptoms should prompt a visit to your physician for evaluation immediately.

What Treatments Are Available for Opioid Use Disorder?
• Medications like methadone and buprenorphine are the most effective treatment. These medications have been proven to prevent cravings and reduce opioid related deaths by up to 50%.
• Medications for opioid use disorder are intended for long-term use, similar to blood pressure pills. Stopping them can increase the risk for returning to opioid use (relapse) and death.
• Methadone has been successfully used for over 50 years to treat opioid use disorder. It is taken daily while observed at a specialized treatment program.
• Buprenorphine is typically a daily pill that can be taken at home with a prescription from a licensed provider.
• Depot Naltrexone is a monthly injection that blocks the action of opioids. Evidence for its effectiveness is weaker than for methadone and buprenorphine.
• Naloxone reverses bad reactions and overdose from opioids and can save someone’s life. It is available as an easy-to-use nasal spray. If you or someone you know uses opioids, you should have this medication stored where it is easy to find in case of an emergency.
• Counseling
  • Counseling and support groups can increase the effectiveness of medication-based treatment. Counseling should be offered in addition to medications whenever possible. It should not be used as a substitute for medication-based treatment.
• “Detox” Models
  • There can be a lot of pressure to “just quit” using opioids, and several centers offer detox services. Detox alone is not as effective as medication-based treatment and is potentially dangerous. Evidence shows that people often return to opioid use soon after detox treatment, putting them at especially high risk of overdose death.
  • Sometimes detox may be used to transition to monthly naltrexone injections. This is more effective than detox alone. However, methadone and buprenorphine are the most proven treatments.

Common Misconceptions About Opioid Use

<table>
<thead>
<tr>
<th>Myths</th>
<th>Facts</th>
</tr>
</thead>
<tbody>
<tr>
<td>Opioid addiction is a choice at will failure.</td>
<td>Opioid addiction is a medical condition with a biochemical basis and effective treatments.</td>
</tr>
<tr>
<td>Detox is a sufficient treatment for opioid addiction.</td>
<td>Detox alone is not recommended. FDA-approved medications save lives and should be a part of all treatment regimens.</td>
</tr>
<tr>
<td>Methadone and buprenorphine treatments are just replacing one drug with another.</td>
<td>Medication assisted treatment reduces craving and prevents withdrawal. Medications reduce opioid related death by up to 50%.</td>
</tr>
<tr>
<td>One has to be in an addiction treatment program in order to access medications for opioid use disorder.</td>
<td>Medications such as buprenorphine and naltrexone can be prescribed by addiction specialists and licensed primary care doctors. Ask your doctor if they are licensed to prescribe buprenorphine.</td>
</tr>
</tbody>
</table>

For More Information

- SAMHSA Patient Information
  [https://www.samhsa.gov/medication-assisted-treatment/treatment](https://www.samhsa.gov/medication-assisted-treatment/treatment)
- National Institutes of Health
  [https://www.drugabuse.gov/publications/research-reports/medications-to-treat-opioid-addiction/overview](https://www.drugabuse.gov/publications/research-reports/medications-to-treat-opioid-addiction/overview)

Authors: Michael A. Incze, MD, MSEd; Scott Steiger, MD
Published Online: March 18, 2019, doi:10.1001/jamainternmed.2019.0014
Author Affiliations: Department of Medicine, University of California, San Francisco (Incze, Steiger). JAMA Internal Medicine (Incze).
Conflict of Interest Disclosures: None reported.
Section Editor: Michael Incze, MD, MSEd.
What You Need to Know About Opioid Pain Medicines

This guide is for you! Keep this guide and the Medication Guide that comes with your medicine so you can better understand what you need to know about your opioid pain medicine. Go over this information with your healthcare provider. Then, ask your healthcare provider about anything that you do not understand.

What are opioids?

Opioids are strong prescription medicines that are used to manage severe pain.

What are the serious risks of using opioids?

- Opioids have serious risks of addiction and overdose.
- Too much opioid medicine in your body can cause your breathing to stop – which could lead to death. This risk is greater for people taking other medicines that make you feel sleepy or people with sleep apnea.
- Addiction is when you crave drugs (like opioid pain medicines) because they make you feel good in some way. You keep taking the drug even though you know it is not a good idea and bad things are happening to you. Addiction is a brain disease that may require ongoing treatment.

Risk Factors for Opioid Abuse:

- You have:
  » a history of addiction
  » a family history of addiction
- You take medicines to treat mental health problems
- You are under the age of 65 (although anyone can abuse opioid medicines)
- You can get addicted to opioids even though you take them exactly as prescribed, especially if taken for a long time.
- If you think you might be addicted, talk to your healthcare provider right away.
- If you take an opioid medicine for more than a few days, your body becomes physically “dependent.” This is normal and it means your body has gotten used to the medicine. You must taper off the opioid medicine (slowly take less medicine) when you no longer need it to avoid withdrawal symptoms.

How can I take opioid pain medicine safely?

- Tell your healthcare provider about all the medicines you are taking, including vitamins, herbal supplements, and other over-the-counter medicines.
- Read the Medication Guide that comes with your prescription.
- Take your opioid medicine exactly as prescribed.
- Do not cut, break, chew, crush, or dissolve your medicine. If you cannot swallow your medicine whole, talk to your healthcare provider.
- When your healthcare provider gives you the prescription, ask:
  » How long should I take it?
  » What should I do if I need to taper off the opioid medicine (slowly take less medicine)?
- Call your healthcare provider if the opioid medicine is not controlling your pain. Do not increase the dose on your own.
- Do not share or give your opioid medicine to anyone else. Your healthcare provider selected this opioid and the dose just for you. A dose that is okay for you could cause an overdose and death for someone else. Also, it is against the law.
- Store your opioid medicine in a safe place where it cannot be reached by children or stolen by family or visitors to your home. Many teenagers like to experiment with pain medicines. Use a lock-box to keep your opioid medicine safe. Keep track of the amount of medicine you have.
- Do not operate heavy machinery until you know how your opioid medicine affects you. Your opioid medicine can make you sleepy, dizzy, or lightheaded.

What should I avoid taking while I am taking opioids?

Unless prescribed by your healthcare provider, you should avoid taking alcohol or any of the following medicines with an opioid because it may cause you to stop breathing, which can lead to death:

- Alcohol: Do not drink any kind of alcohol while you are taking opioid medicines.
- Benzodiazepines (like Valium or Xanax)
- Muscle relaxants (like Soma or Flexeril)
- Sleep medicines (like Ambien or Lunesta)
- Other prescription opioid medicines
What other options are there to help with my pain?

Opioids are not the only thing that can help you control your pain. Ask your healthcare provider if your pain might be helped with a non-opioid medication, physical therapy, exercise, rest, acupuncture, types of behavioral therapy, or patient self-help techniques.

What is naloxone?

- Naloxone is a medicine that treats opioid overdose. It is sprayed inside your nose or injected into your body.
- Use naloxone if you have it and call 911 or go to the emergency room right away if:
  - You or someone else has taken an opioid medicine and is having trouble breathing, is short of breath, or is unusually sleepy
  - A child has accidentally taken the opioid medicine or you think they might have
- Giving naloxone to a person, even a child, who has not taken an opioid medicine will not hurt them.

Naloxone is never a substitute for emergency medical care. Always call 911 or go to the emergency room if you’ve used or given naloxone.

Where can I get naloxone?

- There are some naloxone products that are designed for people to use in their home.
- Naloxone is available in pharmacies. Ask your healthcare provider about how you can get naloxone. In some states, you may not need a prescription.
- When you get your naloxone from the pharmacy, read the Patient Information on how to use naloxone and ask the pharmacist if anything is unclear.
- Tell your family about your naloxone and keep it in a place where you or your family can get to it in an emergency.

When you no longer need your opioid medicine, dispose of it as quickly as possible. The Food and Drug Administration recommends that most opioid medicines be promptly flushed down the toilet when no longer needed, unless a drug take-back option is immediately available. A list of the opioid medicines that can be flushed down the toilet is found here: https://www.fda.gov/drugdisposal

What things should I know about the specific opioid medicine that I am taking?

- Your healthcare provider has prescribed ____________ for you. Read the Medication Guide for this medicine, which is information provided by your pharmacy.
- Remember this other important information about your opioid medicine:

  Dosing instructions: ____________________________________________________________

  Any specific interactions with your medicines: ______________________________________

What if I have more questions?

- Read the Medication Guide that comes with your opioid medicine prescription for more specific information about your medicine.
- Talk to your healthcare provider or pharmacist and ask them any questions you may have.
- Visit: www.fda.gov/opioids for more information about opioid medicines.
Most drugs can be thrown in the household trash, but consumers should take certain precautions before tossing them out, according to the Food and Drug Administration (FDA). A few drugs should be flushed down the toilet. And a growing number of community-based “take-back” programs offer another safe disposal alternative.

**Guidelines for Drug Disposal**

FDA worked with the White House Office of National Drug Control Policy (ONDCP) to develop the first consumer guidance for proper disposal of prescription drugs. Issued by ONDCP in February 2007 and updated in October 2009, the federal guidelines are summarized here:

- Follow any specific disposal instructions on the drug label or patient information that accompanies the medication. Do not flush prescription drugs down the toilet unless this information specifically instructs you to do so.
- Take advantage of community drug take-back programs that allow the public to bring unused drugs to a central location for proper disposal. Call your city or county government’s household trash and recycling service (see blue pages in phone book) to see if a take-back program is available in your community. The Drug Enforcement Administration, working with state and local law enforcement agencies, is sponsoring National Prescription Drug Take Back Days ([www.deadiversion.usdoj.gov](http://www.deadiversion.usdoj.gov)) throughout the United States.
- If no instructions are given on the drug label and no

---

**Take drugs out of their original containers and mix them with an undesirable substance, such as used coffee grounds ...**
take-back program is available in your area, throw the drugs in the household trash, but first:
- Take them out of their original containers and mix them with an undesirable substance, such as used coffee grounds or kitty litter. The medication will be less appealing to children and pets, and unrecognizable to people who may intentionally go through your trash.
- Put them in a sealable bag, empty can, or other container to prevent the medication from leaking or breaking out of a garbage bag.

FDA's Deputy Director of the Office of Compliance Ilisa Bernstein, Pharm.D., J.D., offers some additional tips:
- Before throwing out a medicine container, scratch out all identifying information on the prescription label to make it unreadable. This will help protect your identity and the privacy of your personal health information.
- Do not give medications to friends. Doctors prescribe drugs based on a person's specific symptoms and medical history. A drug that works for you could be dangerous for someone else.
- When in doubt about proper disposal, talk to your pharmacist.

Bernstein says the same disposal methods for prescription drugs could apply to over-the-counter drugs as well.

**Why the Precautions?**

Disposal instructions on the label are part of FDA's "risk mitigation" strategy, says Capt. Jim Hunter, R.Ph., M.P.H., senior program manager on FDA's Controlled Substance Staff. When a drug contains instructions to flush it down the toilet, he says, it's because FDA, working with the manufacturer, has determined this method to be the most appropriate route of disposal that presents the least risk to safety.

Drugs such as powerful narcotic pain relievers and other controlled substances carry instructions for flushing to reduce the danger of unintentional use or overdose and illegal abuse.

For example, the fentanyl patch, an adhesive patch that delivers a potent pain medicine through the skin, comes with instructions to flush used or leftover patches. Too much fentanyl can cause severe breathing problems and lead to death in babies, children, pets, and even adults, especially those who have not been prescribed the drug.

"Even after a patch is used, a lot of the drug remains in the patch," says Hunter, "so you wouldn't want to throw something in the trash that contains a powerful and potentially dangerous narcotic that could harm others."

**Environmental Concerns**

Despite the safety reasons for flushing drugs, some people are questioning the practice because of concerns about trace levels of drug residues found in surface water, such as rivers and lakes, and in some community drinking water supplies. However, the main way drug residues enter water systems is by people taking medications and then naturally passing them through their bodies, says Raanan Bloom, Ph.D., an environmental assessment expert in FDA's Center for Drug Evaluation and Research. "Most drugs are not completely absorbed or metabolized by the body, and enter the environment after passing through waste water treatment plants."

A company that wants FDA to approve its drug must submit an application package to the agency. FDA requires, as part of the application package, an assessment of how the drug's use would affect the environment. Some drug applications are excluded from the assessment requirement, says Bloom, based on previous agency actions.

"For those drugs for which environmental assessments have been required, there has been no indication of environmental effects due to flushing," says Bloom. In addition, according to the Environmental Protection Agency, scientists to date have found no evidence of adverse human health effects from pharmaceutical residues in the environment.

Nonetheless, FDA does not want to add drug residues into water systems unnecessarily, says Hunter. The agency reviewed its drug labels to identify products with disposal directions recommending flushing or disposal down the sink. This continuously revised listing can be found at FDA's Web page on Disposal of Unused Medicines (www.fda.gov/Drugs/ResourcesForYou/ Consumers/BuyingUsingMedicineSafely/ EnsuringSafeUseofMedicine/Safe DisposalofMedicines/ucm186187.htm).

Another environmental concern lies with inhalers used by people who have asthma or other breathing problems, such as chronic obstructive pulmonary disease. Traditionally, many inhalers have contained chlorofluorocarbons (CFC's), a propellant that damages the protective ozone layer. The CFC inhalers are being phased out and replaced with more environmentally friendly inhalers.

Depending on the type of product and where you live, inhalers and aerosol products may be thrown into household trash or recyclables, or may be considered hazardous waste and require special handling. Read the handling instructions on the label, as some inhalers should not be punctured or thrown into a fire or incinerator. To ensure safe disposal, contact your local trash and recycling facility.
DISPOSAL ACT: GENERAL PUBLIC FACT SHEET

On September 8, 2014, the Drug Enforcement Administration (DEA) made available for public view a final rule regarding the disposal of pharmaceutical controlled substances in accordance with the Controlled Substance Act, as amended by the Secure and Responsible Drug Disposal Act of 2010 (“Disposal Act”). The final rule is available for public view at http://www.federalregister.gov/public-inspection. The final rule will officially publish in the Federal Register on September 9, 2014, and will be available on http://www.regulations.gov, and our website, http://www.DEAdiversion.usdoj.gov. This General Public Fact Sheet contains a general summary of some of the effects of the new rule on the general public. For detailed information, please visit our website or contact your local DEA office.

1. What is the Disposal Act?
   • The Disposal Act amended the Controlled Substances Act (CSA) to give the DEA authority to promulgate new regulations, within the framework of the CSA, that will allow ultimate users to deliver unused pharmaceutical controlled substances to appropriate entities for disposal in a safe and effective manner consistent with effective controls against diversion. The goal of the Disposal Act is to encourage public and private entities to develop a variety of methods of collection and disposal in a secure, convenient, and responsible manner.

2. Who is an “ultimate user”?
   • The CSA defines an “ultimate user” as “a person who has lawfully obtained, and who possesses, a controlled substance for his own use or for the use of a member of his household or for an animal owned by him or a member of his household.”

3. Are my options for disposing of pharmaceuticals more limited now?
   • No. These regulations don’t limit the ways that ultimate users may dispose of pharmaceutical controlled substances—they expand them. The DEA’s new regulations outline the methods by which pharmaceutical controlled substances may be transferred to authorized collectors for disposal. Ultimate users now have expanded options to safely and responsibly dispose of their unused and unwanted, lawfully-possessed pharmaceutical controlled substances: through collection receptacles, mail-back packages, and take-back events.

4. May I continue to dispose of pharmaceutical controlled substances using methods that were valid prior to this final rule?
   • Yes. Any method of pharmaceutical disposal that was valid prior to these regulations continues to be valid.
   • For example, ultimate users may continue to utilize the FDA and EPA guidelines for the disposal of medicines, available through the DEA website at http://www.deadiversion.usdoj.gov/drug_disposal/index.html.
5. Will there still be take-back events every six months?

- Law enforcement may continue to conduct take-back events at any time. Any person or community group, registrant or non-registrant, may partner with law enforcement to conduct take-back events. The DEA encourages communities to partner with law enforcement to continue to conduct take-back events.

- The next DEA-sponsored nationwide take back event will be on September 27, 2014. The DEA will not continue to sponsor nationwide take-back events in order to prevent competing with local take-back efforts conducted in accordance with the new regulations.

6. Can I dispose of a friend or family member’s pharmaceutical controlled substances for them?

- You may dispose of a member of your household’s unused or unwanted pharmaceutical controlled substances. But, if they are not a member of your household, you may not dispose of their pharmaceutical controlled substances on their behalf. Only ultimate users may dispose of pharmaceutical controlled substances. An ultimate user, which includes a household member of the person or pet who was prescribed the medication, may transfer pharmaceutical controlled substances to authorized collectors or law enforcement via a collection receptacle, mail-back package, or take-back event.

- Exceptions:
  - If someone dies while in lawful possession of pharmaceutical controlled substances, any person lawfully entitled to dispose of the decedent’s property may dispose of the pharmaceutical controlled substances; and
  - A long-term-care facility may dispose of a current or former resident’s pharmaceutical controlled substances.

7. My mother has pharmaceutical controlled substances delivered to her home. She passed away, and I would like to dispose of her unused pharmaceutical controlled substances. I did not live with her. Can I dispose of them?

- Yes, so long as you are lawfully entitled to dispose of her property, you may dispose of her unused pharmaceutical controlled substances.

8. How can I find a collection receptacle location near me?

- Members of the public may call the DEA’s Registration Call Center at 1-800-882-9539 to find a collection receptacle location near them.

9. I live in a rural location. There are no collection receptacles, mail-back programs, or take-back events in the vicinity. How can I safely and securely dispose of my unwanted pharmaceutical controlled substances?

- There are no restrictions on using a mail-back package obtained from another state. You may dispose of your unwanted pharmaceutical controlled substances in a mail-back package that you received from another state, even if the mail-back package is delivered to a location outside of your state.
Additionally, these regulations expand—not limit—the options that ultimate users have to dispose of unwanted pharmaceutical controlled substances. You may continue to dispose of your unwanted pharmaceutical controlled substances using the lawful methods you used prior to the effective date of the new regulations, as long as those methods are consistent with Federal, State, tribal, or local laws and regulations, including surrendering pharmaceutical controlled substances to law enforcement.

10. Can I dispose of illicit drugs through a collection receptacle, mail-back package, or take-back event? How can I safely and securely dispose of my unwanted marijuana?

- No. Persons may not dispose of illicit drugs (e.g., schedule I controlled substances such as marijuana, heroin, LSD) through any of the three disposal methods.

- Persons may not dispose of any controlled substances that they do not legally possess. This includes schedules II-V controlled substances that are illegally obtained and possessed.

11. I don’t have a mail-back package, but I remember the address from the last mail-back package I used. Can I mail pharmaceutical controlled substances to that address without an official mail-back package?

- No. Persons must use the mail-back package that was provided by an authorized collector or one of their partners. The mail-back package must meet certain specifications, to include having a unique identification number. If an authorized collector receives a sealed mail-back package that they did not provide, the collector must reject it, or if they inadvertently accept it, they must notify the DEA.

- If persons would like to use a mail-back package and don’t possess one, they may contact an authorized collector to obtain one.

12. Can I dispose of my insulin syringes through one of the disposal methods? What about my child’s asthma inhaler?

- No. Persons may not dispose of any dangerous, hazardous, or non-compliant items in a collection receptacle or a mail-back package. This includes medical sharps and needles (e.g., insulin syringes), and compressed cylinders or aerosols (e.g., asthma inhalers).

- Other non-compliant items that may not be placed into a collection receptacle or mail-back package include iodine-containing medications and mercury-containing thermometers.

- Accepting these materials places the collector at risk, and might cause a dangerous situation. You should continue to use any valid methods you currently utilize to dispose of those medications and medical implements.

- Carefully review the authorized collector’s instructions for what is and is not acceptable to place into the collection receptacle or mail-back package. If you have any questions, you should ask an employee of the authorized collector.
13. Can my pharmacy or other collector force me to give personal information, like my name, my prescription information, or my physician information?

- No. A collector may not force anyone to provide any personal information about themselves, their prescription, or their physician.

- In order to protect personally identifiable information, the DEA encourages persons not to place prescription bottles in collection receptacles or mail-back packages.

14. What happens to my pharmaceuticals after I dispose of them? Can they be sold, given away, re-packaged, or re-dispensed for use by another patient? Can they be otherwise recycled?

- Pharmaceutical controlled substances transferred from ultimate users to authorized collectors via either collection receptacles or mail-back programs shall be securely stored or transferred until rendered non-retrievable. They may not be re-sold, donated, repackaged, or re-dispensed. Currently, the most common method of rendering pharmaceutical controlled substances non-retrievable is incineration.

15. Are there environmental impacts?

- Disposed pharmaceuticals must be rendered non-retrievable in compliance with all applicable Federal, State, tribal, and local laws, including those relating to environmental protection. By expanding options on how ultimate users may dispose of their pharmaceutical controlled substances, fewer of these substances may end up in our nation’s water system.
Original Research Article

SCOPE of Pain: An Evaluation of an Opioid Risk Evaluation and Mitigation Strategy Continuing Education Program

Daniel P. Alford, MD, MPH,*† Lara Zisblatt, EdD, MA,* Pamela Ng, MSc,‡ Sean M. Hayes, PsyD,‡ Sophie Peloquin, MMedSc,‡ Ilana Hardesty, BA,* and Julie L. White, MS*

*The Barry M. Manuel Office of Continuing Medical Education, Boston University School of Medicine, Boston, Massachusetts, USA; †Department of Medicine, Boston Medical Center, Boston, Massachusetts, USA; ‡Performance Improvement Division, AXDEV Group Inc., Brossard, Quebec, Canada

Correspondence to: Daniel P. Alford, MD, MPH, FACP, FASAM, Boston Medical Center, 801 Massachusetts Avenue, Crosstown 2, Boston, MA 02118, USA. Tel: 617-414-3747; Fax: 617-414-4676; E-mail: dan.alford@bmc.org.

Funding sources: The SCOPE of Pain program was funded by an independent educational grant awarded by the manufacturers of extended-release (ER) and long-acting (LA) opioid analgesics, collectively known as the Risk Evaluation and Mitigation Strategy (REMS) Program Companies or RPC (http://www.er-la-opioidrems.com/lwgUI/remsv/home.action).

Disclosure: The authors do not have any relationships to disclose.

Method. Participants of the 3-h SCOPE of Pain training completed pre-, immediate post- and 2-month post-assessments.

Subjects. The primary target group (n = 2,850), and a subset (n = 476) who completed a 2-month post-assessment, consisted of clinicians licensed to prescribe ER/LA opioid analgesics, who care for patients with chronic pain and who completed the 3-h training between February 28, 2013 and June 13, 2014.

Results. Immediately post-program, there was a significant increase in correct responses to knowledge questions (60% to 84%, $P \leq 0.02$) and 87% of participants planned to make practice changes. At 2-months post-program, there continued to be a significant increase in correct responses to knowledge questions (60% to 69%, $P \leq 0.03$) and 67% reported increased confidence in applying safe opioid prescribing care and 86% reported implementing practice changes. There was also an improvement in alignment of desired attitudes toward safe opioid prescribing.

Conclusions. The SCOPE of Pain program improved knowledge, attitudes, confidence, and self-reported clinical practice in safe opioid prescribing. This national REMS program holds potential to improve the safe use of opioids for the treatment of chronic pain.

Key Words. Chronic Pain; Opioid Medications; Continuing Education

Introduction

Chronic pain affects approximately 100 million in the United States, making it one of the most common reasons patients seek medical care [1,2]. Undertreated chronic pain causes reduced function and quality of life [3], and is associated with increased rates of suicidality [4,5]. However, more aggressive chronic pain management with opioid analgesics over the past two decades has been associated with an increase in prescription opioid misuse, the US Food and Drug Administration (FDA) mandated a Risk Evaluation and Mitigation Strategy (REMS) requiring manufacturers of extended-release/long-acting (ER/LA) opioid analgesics to fund continuing education based on a FDA Blueprint. This article describes the Safe and Competent Opioid Prescribing Education (SCOPE of Pain) program, an ER/LA opioid analgesic REMS program, and its impact on clinician knowledge, confidence, attitudes, and self-reported clinical practice.
Mitigation strategy (REMS) required of manufacturers of opioid analgesics [31]. In July 2012, the US Food and Drug Administration approved a single shared Risk Evaluation and Mitigation Strategy (REMS) required of manufacturers of extended-release/long-acting (ER/LA) opioid analgesics to promote safe use of these medications [32]. While most FDA-mandated REMS programs include medication guides and communication plans and are associated with a single medication, this REMS requires all manufacturers to jointly fund accredited continuing education for the approximately 320,000 ER/LA opioid prescribers in the United States [33]. The FDA created the Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioid Analgesics (“FDA Blueprint”) to define the content that must be included in REMS educational programs [34,35]. Boston University School of Medicine (BUSM), the first Continuing Medical Education provider to receive ER/LA opioid REMS funding, launched its Safe and Competent Opioid Prescribing Education (SCOPE of Pain) program on February 28, 2013.

As a new national strategy, the effectiveness of requiring manufacturers to contribute funds to support independent education based on an FDA Blueprint is unknown. The purpose of this study is to describe the SCOPE of Pain program and report on its impact on participants’ knowledge, attitudes, confidence, and self-reported practice. As the first report on an ER/LA opioid REMS program, the data from this project can offer an initial assessment of effectiveness of this national strategy to improve practices.

**Methods**

**SCOPE of Pain Description**

SCOPE of Pain is based on the FDA Blueprint [36] and is offered as a 3-h live or online activity available at www.scopeofpain.org. The live programs included 20 half-day standalone meetings across the United States in 16 different states. The live and online curricula are identical and presented using a clinical case involving three separate visits: initial visit—assessing chronic pain and opioid misuse risk; one week later—initiating (continuing) opioid therapy safely and months later—assessing and managing aberrant medication taking behaviors. This allows participants to apply the ER/LA opioid REMS content to a common clinical scenario. SCOPE of Pain was created based on an existing online and live education program we developed in 2010 called “Safe and Effective Opioid Prescribing for Chronic Pain” (www.opioidprescribing.org) that had trained approximately 19,000 clinicians. A team of 13 faculty with expertise in pain management, addiction, primary care, and medical education created the original Opioid Prescribing program and a team of five experts tailored that content to cover all aspects of the FDA Blueprint to make the program REMS compliant. While the original content was well aligned with the FDA Blueprint, specific topics were expanded including opioid prescribing using a risk/benefit framework, effective communication skills for assessing and managing aberrant medication taking behaviors and strategies for team-based care. While the content was not formally tested, evaluation data from the over 5,000 participants of the original Opioid Prescribing program were used to inform the creation of the SCOPE of Pain program.

To ensure that the curriculum covered all FDA Blueprint elements, BUSM conducted both internal and external audit processes and an additional independent audit was conducted by the Accreditation Council for Continuing Medical Education (ACCME). The Boston University Medical Campus Institutional Review Board (IRB) determined this evaluation to be exempt from further IRB review.

**Outcomes**

A repeated measures design was used to assess the impact of SCOPE of Pain in changing clinicians’ knowledge, attitudes, confidence, and clinical practice. Data were collected from participants at three time points: 1) pre-program (PRE), 2) immediate post-program (IMMED), and 3) 2-months post-program (2MO) (Figure 1). This design assessed changes over time with specific attention to increased alignment with practices described in the FDA Blueprint.

Items to assess participants’ changes were designed by a multidisciplinary team including: a faculty expert in opioid prescribing, primary care and addiction medicine (DPA), experts in educational design (LZ, JLW, IH) and experts in outcomes assessments (SMH, SP, PN). Items were developed with the four key metrics of change that SCOPE of Pain targets: 1) twenty (20) items to assess improvements in knowledge (of which only 10 were repeated at 2MO to minimize respondents’ burden and allow for additional questions about changes in performance), 2) six (6) items regarding change in
participant confidence to manage patients with chronic pain, 3) thirteen (13) items assessing change in attitudes (motivation and willingness) when treating patients with chronic pain and using guideline-based care; and 4) multiple items addressing changes in clinical practice including: a) two (2) items assessing intention to change clinical practice; b) seven (7) items assessing participants’ reported changes in clinical performance; c) one (1) item assessing number of changes implemented; and d) one (1) item assessing barriers to implementing change in practice.

To be REMS compliant, the assessment was required to have knowledge-based questions from each of the six sections of the FDA Blueprint [36]. The course director (DPA) who specializes in primary care, pain management and addiction medicine and program education experts (LZ, IH, JLW) determined which elements from each section were best suited for knowledge-based questions and most relevant to practicing clinicians. Confidence and performance questions were based on guideline-based [17–21] safe opioid prescribing practices (e.g., risk and benefit assessments, monitoring and management strategies) and important communication skills. Each item was tested and retested for face validity, and linked explicitly to elements within the six sections of the FDA Blueprint for content validity. All questions were tested by primary care clinicians from general internal medicine and family medicine and pain and addiction medicine experts. The questionnaires used did not undergo validity testing as the evaluation was designed for a new educational program without a known gold standard or preexisting criterion by which to validate.

The PRE/IMMED/2MO items are quantitative using forced choice (drop-down) options. Knowledge-testing questions were a combination of multiple nominal choice responses (including dichotomous true/false questions and item-matching questions). Likert-type response formats were used for self-reported assessment of confidence, attitudes, and clinical practice.

### Participant Recruitment

The primary target group included clinicians who manage patients with chronic pain longitudinally. This included primary care and other specialties that manage chronic pain such as hematology, oncology, rheumatology, rehabilitation medicine, sports medicine, neurology, orthopedics, and anesthesiology. While promotion for the program and collection of pre-assessment (PRE) and post-assessment (IMMED and 2MO) data extended beyond the primary target group, only participants whose specialty indicated a likelihood for managing chronic pain were included in this study.

All participants completed the pre-assessment on registration. Participants were required to complete the immediate post-assessment to receive continuing education credit. A drawing for an e-book reader was used to incentivize completion of the 2-month post-assessment. As an email address was collected for all participants, an email was automatically sent to all participants at 60 days, with a reminder at 63 days, and 66 days post-activity for those who did not complete the assessment.

### Analyses

Using IBM SPSS 22.0 software (IBM Corporation, Armonk, NY), frequencies and cross-tabulations were calculated for each item. Paired *t*-tests were used to identify participant knowledge change (PRE vs IMMED) and knowledge maintenance (PRE vs 2MO). Paired *t*-tests were also used to compare participants’ attitudes and clinical practice (PRE vs 2MO) to establish change in clinical practice two months after participation.
Participants

A total of 10,566 participants completed SCOPE of Pain between February 28, 2013 and June 13, 2014. Twenty-seven percent (2,850/10,566) were considered our primary target group (defined as being physicians, advanced practice nurses, or physician assistants licensed to prescribe opioid analgesics and a member of 13 specialties that routine manage patients with chronic pain (Table 1). The primary target group was made up of mostly physicians (69%), primary care specialties (75%), and clinicians practicing for greater than 10 years (60%). A majority of participants (77%) completed the training online rather than live. All 2,850 participants completed the PRE and IMMED assessments. Of those, 17% (476/2,850) completed the 2MO assessment. Table 1 presents the socio-demographics for the primary target group who completed SCOPE of Pain compared with the subset who also completed the 2MO assessment. The two groups were similar, except for a higher proportion of advanced practice nurses completing the 2MO assessment ($P < 0.001$).

The following section focuses on the findings divided into two sections 1) IMMED and 2) 2MO assessment. Findings are grouped by the type of expected impact of SCOPE of Pain on participants (knowledge, confidence, attitudes, and clinical practice).

Table 1 SCOPE of Pain participant characteristics

<table>
<thead>
<tr>
<th>Profession n, (%)</th>
<th>Primary Target Group (n = 2,850)</th>
<th>Completed 2-Month Post-Program Assessment (n = 476)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physician</td>
<td>1,955 (69%)</td>
<td>288 (61%)</td>
</tr>
<tr>
<td>Advance practice nurse*</td>
<td>706 (25%)</td>
<td>154 (32%)</td>
</tr>
<tr>
<td>Physician assistant</td>
<td>189 (6%)</td>
<td>34 (7%)</td>
</tr>
<tr>
<td>Specialty n, (%)</td>
<td>Family practice 1,179 (41%)</td>
<td>235 (49%)</td>
</tr>
<tr>
<td></td>
<td>Internal medicine 791 (28%)</td>
<td>117 (25%)</td>
</tr>
<tr>
<td></td>
<td>Anesthesiology 183 (6%)</td>
<td>26 (6%)</td>
</tr>
<tr>
<td></td>
<td>Pediatrics 159 (6%)</td>
<td>19 (4%)</td>
</tr>
<tr>
<td></td>
<td>Orthopedic surgery 105 (4%)</td>
<td>14 (3%)</td>
</tr>
<tr>
<td></td>
<td>Physical medicine and rehabilitation 115 (4%)</td>
<td>17 (4%)</td>
</tr>
<tr>
<td></td>
<td>Hematology and oncology 85 (3%)</td>
<td>12 (2%)</td>
</tr>
<tr>
<td></td>
<td>Obstetrics and gynecology 83 (3%)</td>
<td>12 (2%)</td>
</tr>
<tr>
<td></td>
<td>Neurology 63 (2%)</td>
<td>11 (2%)</td>
</tr>
<tr>
<td></td>
<td>Rheumatology 52 (2%)</td>
<td>5 (1%)</td>
</tr>
<tr>
<td></td>
<td>Infectious disease 25 (1%)</td>
<td>6 (1%)</td>
</tr>
<tr>
<td></td>
<td>Sports medicine 7 (0.2%)</td>
<td>1 (0.2%)</td>
</tr>
<tr>
<td></td>
<td>Adolescent medicine 3 (0.1%)</td>
<td>1 (0.2%)</td>
</tr>
<tr>
<td>Years of practice n, (%)</td>
<td>1–5 years 659 (23%)</td>
<td>118 (25%)</td>
</tr>
<tr>
<td></td>
<td>6–10 years 405 (14%)</td>
<td>74 (16%)</td>
</tr>
<tr>
<td></td>
<td>11–20 years 783 (27%)</td>
<td>116 (24%)</td>
</tr>
<tr>
<td></td>
<td>&gt;21 years 950 (33%)</td>
<td>160 (34%)</td>
</tr>
<tr>
<td></td>
<td>Other 21 (2%)</td>
<td>8 (1%)</td>
</tr>
<tr>
<td>Participant type n, (%)</td>
<td>Online 2,203 (77%)</td>
<td>315 (66%)</td>
</tr>
<tr>
<td></td>
<td>Live 647 (23%)</td>
<td>161 (34%)</td>
</tr>
</tbody>
</table>

*Significant difference between the group that completed the SCOPE of Pain program and those that completed the 2-MO post-assessment at the $P = 0.05$ level.

Results

Participants

A total of 10,566 participants completed SCOPE of Pain between February 28, 2013 and June 13, 2014. Twenty-seven percent (2,850/10,566) were considered our primary target group (defined as being physicians, advanced practice nurses, or physician assistants licensed to prescribe opioid analgesics and a member of 13 specialties that routine manage patients with chronic pain (Table 1). The primary target group was made up of mostly physicians (69%), primary care specialties (75%), and clinicians practicing for greater than 10 years (60%). A majority of participants (77%) completed the training online rather than live. All 2,850 participants completed the PRE and IMMED assessments. Of those, 17% (476/2,850) completed the 2MO assessment. Table 1 presents the socio-demographics for the primary target group who completed SCOPE of Pain compared with the subset who also completed the 2MO assessment. The two groups were similar, except for a higher proportion of advanced practice nurses completing the 2MO assessment ($P < 0.001$).

The following section focuses on the findings divided into two sections 1) IMMED and 2) 2MO assessment. Findings are grouped by the type of expected impact of SCOPE of Pain on participants (knowledge, confidence, attitudes, and clinical practice).

IMMED: Immediate Post-Program Assessment (N = 2,850)

Knowledge. A significantly higher proportion of participants responded correctly to the 20 knowledge items in the IMMED compared with PRE, 84% vs 60% ($P \leq 0.02$), respectively.

Intention to Change. Immediate post-program, 87% of participants stated they were planning to make at least one change to align their practice with guideline-based
The most frequently stated changes were 1) to improve opioid prescribing documentation (56%); 2) to implement or improve opioid prescribing patient education or communication (53%); and 3) to institute or improve Patient-Prescriber Agreements (47%).

2MO: 2-Months Post-Program Assessment (N = 476)

Knowledge Maintenance. Compared with the PRE, the proportion of correct responses at 2MO was significantly (P < 0.03) higher for 7 out of the 10 knowledge questions on opioid misuse risk factors and risk assessment. While the improvement in correct responses in the 2MO (69%) compared with PRE (60%) was modest, it was significant.

Confidence. Approximately two-thirds of participants reported increased confidence in guideline-based opioid prescribing practices including assessing pain and opioid misuse risk and assessing, monitoring and discussing opioid benefits, risks, and harms with their patients (Table 2).

Attitudes. Participants reported on average an increase of 9% in alignment with increased trust in their patients and with guideline-based care (P < 0.01). For example, to the statement I trust that available pain scales provide reliable assessment of pain in my patients, 48% of participants responded 4 or 5 on the agreement scale (1 is completely disagree and 5 is completely agree) at 2MO, as compared with 31% at PRE, a 17% increase (P < 0.01). For the items for which a decrease in agreement was desired, the proportion of participants who reported being in agreement decreased on average by 7% (P ≤ 0.02) (Table 3).

Clinical Practice (Patient Communication and Guideline-Based Care)

Patient Communication (Table 4)

Improvements were made in all seven recommended communication skills with a significant increase from PRE to 2MO in participants reporting performing these behaviors with most/all of their patients with chronic pain from an average of 64% to 78% (P < 0.01), respectively.

Guideline-Based Care (Table 5)

When presented with nine specific clinical practice changes at 2MO: 68% had either partially or fully improved their opioid prescribing documentation in patient medical records, 67% reported having implemented or improved patient education and communication relating to opioid prescribing and 52% reported having implemented/improved urine drug testing for monitoring opioid adherence and misuse. Approximately 60% reported partially/fully implementing four or more changes in their practice with 35% implementing 7–9 changes.

Barriers to Change

Eighty-three percent of participants reported at least one barrier to making practice change. The most significant barriers reported were patients’ resistance to change (23%) followed by other providers’ or institutional resistance to change (17%).

Table 2 Changes in confidence in performing guideline-based clinical practices

<table>
<thead>
<tr>
<th>Statements</th>
<th>2-Months Post-Program Assessment (n = 476)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Rate your confidence in your ability to accomplish each</td>
</tr>
<tr>
<td></td>
<td>of the following as you attended the program:</td>
</tr>
<tr>
<td></td>
<td>Increased</td>
</tr>
<tr>
<td>Assess pain in a new patient?</td>
<td>65% (311)</td>
</tr>
<tr>
<td>Assess the potential benefit and risk of opioids for chronic pain in a new patient?</td>
<td>72% (341)</td>
</tr>
<tr>
<td>Communicate and collaborate with patients around opioid initiation?</td>
<td>71% (338)</td>
</tr>
<tr>
<td>Monitor patients on chronic opioid therapy for opioid misuse, including addiction and diversion?</td>
<td>63% (301)</td>
</tr>
<tr>
<td>Effectively and efficiently assess your patients for potential misuse of opioids?</td>
<td>67% (318)</td>
</tr>
<tr>
<td>Effectively communicate with your patients when treatment has shown no benefit</td>
<td>63% (300)</td>
</tr>
</tbody>
</table>


**Discussion**

*SCOPE of Pain*, an ER/LA opioid REMS program, resulted in improvements in knowledge and attitudes about safe opioid prescribing, as well as increases in self-reported confidence and implementation of improved communication skills and guideline-based opioid prescribing practices. There were increases in clinician trust in patients with chronic pain and in the tools available to assess patients’ pain and to detect opioid misuse.

For the first time, an FDA REMS included the mandate for independent continuing education to be funded by commercial entities to help mitigate the risks of their medications. While education is a natural part of any REMS, whether you must teach about a mandated registry or how to document safe-use conditions (e.g., pregnancy tests), this REMS included an extensive, prescribed curriculum developed by the FDA and not the providers of the education. This is distinct from the usual process of how content for continuing education is created by the provider.

While the need for prescriber education is universally accepted, this REMS has been met with some skepticism [37]. This study is a first step in evaluating this national strategy of clinician continuing education as a way to improve safe opioid prescribing. The comparison among PRE, IMMED, and 2MO assessment data suggest that not only did clinicians learn more about safe opioid prescribing, but they have more confidence and

---

**Table 3** Changes in attitude in managing patients with chronic pain (n = 476)

<table>
<thead>
<tr>
<th>Statement</th>
<th>Desired Change</th>
<th>Pre-Program</th>
<th>2-Month Post-Program</th>
<th>% Change</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Statements that should have MORE agreement</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I trust that most of my patients with chronic pain are able to provide an accurate self-assessment of their pain</td>
<td>†</td>
<td>48% (227)</td>
<td>50% (239)</td>
<td>+2%</td>
<td>0.314</td>
</tr>
<tr>
<td>I trust that available pain scales provide reliable assessment of pain in my patients</td>
<td>†</td>
<td>31% (149)</td>
<td>48% (230)</td>
<td>+17%</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>It is my responsibility and role to discuss with my patients not to give away their medications to relatives or friends</td>
<td>†</td>
<td>92% (437)</td>
<td>96% (459)</td>
<td>+4%</td>
<td>0.001</td>
</tr>
<tr>
<td>I am comfortable responding to family calls about my patients’ possible misuse of opioids</td>
<td>†</td>
<td>50% (237)</td>
<td>62% (296)</td>
<td>+12%</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>Statements that should have LESS agreement</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>There is no reliable way to identify those of my patients who are drug-seekers</td>
<td>‡</td>
<td>29% (138)</td>
<td>21% (102)</td>
<td>−8%</td>
<td>0.020</td>
</tr>
<tr>
<td>Treating and managing patients with chronic pain is time-consuming and frustrating</td>
<td>‡</td>
<td>68% (326)</td>
<td>64% (304)</td>
<td>−4%</td>
<td>0.054</td>
</tr>
<tr>
<td>I will never prescribe ER/LA opioids to a patient with history of mental health issues</td>
<td>‡</td>
<td>16% (77)</td>
<td>17% (82)</td>
<td>+1%</td>
<td>0.564</td>
</tr>
<tr>
<td>I cannot get my patients to be truthful about illicit drug use</td>
<td>‡</td>
<td>29% (137)</td>
<td>22% (107)</td>
<td>−7%</td>
<td>0.004</td>
</tr>
<tr>
<td>I am uncomfortable communicating an unexpected urine drug test result to my patients</td>
<td>‡</td>
<td>24% (112)</td>
<td>20% (97)</td>
<td>−4%</td>
<td>0.187</td>
</tr>
<tr>
<td>I am unsure I am effectively assessing opioids misuse risk in my patients with chronic pain on ER/LA opioids</td>
<td>‡</td>
<td>48% (226)</td>
<td>31% (147)</td>
<td>−4%</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>I suspect there is more I should be doing in the treatment and management of my patients who report chronic pain</td>
<td>‡</td>
<td>76% (360)</td>
<td>58% (275)</td>
<td>−18%</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>I prefer to stop seeing/following a patient who has misused his/her opioid prescription</td>
<td>‡</td>
<td>57% (273)</td>
<td>51% (242)</td>
<td>−6%</td>
<td>0.007</td>
</tr>
<tr>
<td>I would only ask for a urine drug test from a patient that I thought was abusing the opioid prescription</td>
<td>‡</td>
<td>19% (90)</td>
<td>13% (63)</td>
<td>−6%</td>
<td>0.003</td>
</tr>
</tbody>
</table>
Table 4  Changes in patient communication (n = 476)

<table>
<thead>
<tr>
<th>Clinical Performance Item</th>
<th>Pre</th>
<th>Post</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Talk with my patients' previous primary care providers and review prior medical records</td>
<td><img src="image1.png" alt="Graph" /></td>
<td><img src="image2.png" alt="Graph" /></td>
</tr>
<tr>
<td>2. Implement and co-sign a Patient-Prescriber agreement (including informed consent and plan of care)</td>
<td><img src="image3.png" alt="Graph" /></td>
<td><img src="image4.png" alt="Graph" /></td>
</tr>
<tr>
<td>3. Inform my patients about taking medication exactly as prescribed (e.g., don't increase dose; don't crush tablets, etc.)</td>
<td><img src="image5.png" alt="Graph" /></td>
<td><img src="image6.png" alt="Graph" /></td>
</tr>
<tr>
<td>4. Educate my patient about proper storage and disposal of ER/LA Opioids</td>
<td><img src="image7.png" alt="Graph" /></td>
<td><img src="image8.png" alt="Graph" /></td>
</tr>
<tr>
<td>5. Counsel my patients about risk of respiratory depression and overdose.</td>
<td><img src="image9.png" alt="Graph" /></td>
<td><img src="image10.png" alt="Graph" /></td>
</tr>
<tr>
<td>6. Give my patients a patient counselling document and tools as part of the discussions with them when prescribing opioid analgesics</td>
<td><img src="image11.png" alt="Graph" /></td>
<td><img src="image12.png" alt="Graph" /></td>
</tr>
<tr>
<td>7. Explain to my patient the methods I use to monitor opioid misuse (i.e., urine drug tests and/or pill counts)</td>
<td><img src="image13.png" alt="Graph" /></td>
<td><img src="image14.png" alt="Graph" /></td>
</tr>
</tbody>
</table>
were able to make changes to align with guideline-based practices. While knowledge gain did decrease in the 2MO, it did not return to baseline, and in fact continued to be significantly higher than the PRE-assessment. Without repeated exposure deterioration of knowledge is an expected outcome in education studies.

While the evaluation of this REMS education is based on self-reported data and does not include objective measures (e.g., decreases in prescription opioid misuse) to demonstrate the effectiveness of the training, it does demonstrate that education based on content from the FDA, developed by continuing education providers, and funded by commercial interests can still yield a positive impact on self-reported changes in behavior.

There are a growing number of state policy, systems-level, and payer interventions being promulgated to address the prescription opioid misuse problem [31]. While these interventions appear to be efficient solutions to controlling prescription opioid misuse, such blunt instruments risk the unintended consequences of making opioids inaccessible for those that currently or potentially may benefit. In contrast, quality, targeted education can empower clinicians to make appropriate and informed clinical decisions about whether or not to initiate, continue, change or discontinue opioids for each individual patient suffering from chronic pain based on a careful benefit vs risk/harm assessment [38,39]. Educational approaches will maintain access for patients who do, or can, benefit from such medications while mitigating the potential risks to those who are not benefiting or are being harmed. While there has been considerable skepticism about continuing medical education’s (CME) ability to improve clinicians’ practices [40], recent meta-analyses have supported that, overall, CME, especially using serial educational interventions, is effective in changing clinician performance [41,42]. As opposed to regulations limiting clinician practice, education is a tool that can help clinicians develop the nuanced, informed approach necessary for individualizing patient care with regards to safe opioid prescribing.

Questions remain on next steps to enhance the current REMS education. This speaks to the need for a clinician awareness campaign regarding the availability of these REMS trainings. While the REMS program is mandatory

---

**Table 5** Changes in guideline-based practices (n = 476)

<table>
<thead>
<tr>
<th>Changes to Practice</th>
<th>2-Months Post-Program Assessment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>% (n) who partially/fully implemented</td>
</tr>
<tr>
<td><strong>Implement or improve...</strong></td>
<td></td>
</tr>
<tr>
<td>Patient Prescriber “Agreements”</td>
<td>47% (225)</td>
</tr>
<tr>
<td>Informed consent procedures</td>
<td>45% (216)</td>
</tr>
<tr>
<td>Urine drug testing for monitoring</td>
<td>52% (246)</td>
</tr>
<tr>
<td>Pill counts for monitoring</td>
<td>43% (204)</td>
</tr>
<tr>
<td>Patient education or communication strategies</td>
<td>67% (319)</td>
</tr>
<tr>
<td>Office-wide policies/procedures</td>
<td>49% (233)</td>
</tr>
<tr>
<td>Multidisciplinary team approach</td>
<td>48% (227)</td>
</tr>
<tr>
<td>Documentation in patient medical records</td>
<td>68% (325)</td>
</tr>
<tr>
<td>Register/begin using the Prescription Drug Monitoring Program</td>
<td>45% (214)</td>
</tr>
</tbody>
</table>
for the ER/LA opioid manufacturers, it is not mandatory for clinicians [37]. In one primary care survey [43], less than 10% of physicians were “very familiar” with the REMS education. Since the first announcement by the FDA regarding the opioid REMS program there has been debate as to whether clinician education should be mandated and linked to US Drug Enforcement Administration (DEA) licensure [44]. A training requirement is not unprecedented, as there is such a requirement within the Drug Addiction Treatment Act of 2000 [45] (DATA 2000) which limits the prescribing of buprenorphine for the treatment of opioid use disorders to those that have completed an 8-h training. While the DATA 2000 training requirement is highly supported by addiction medicine/psychiatry societies, only a small number of physicians have taken the training, which has resulted in limited access to this life-saving treatment for those who need it [46,47]. Thus, it would be important to link mandated opioid prescribing training to DEA licensure to avoid having clinicians “opt out” of this requirement leading to decreased treatment access and burn-out for those clinicians that “opt in.” However, to make education mandatory there must be evidence that education would positively impact prescription opioid misuse without decreasing appropriate access to prescription opioids. Alternatively the goal could be mandatory demonstration of clinical competence allowing those clinicians well trained in this area to “test out” of the requirement. Finally, including practice-based performance improvement or quality improvement efforts following SCOPE of Pain education may lead to more robust clinical practice changes, but would require a more substantial investment in time and resources [48,49].

With any intervention, education or otherwise, it would be ideal to measure changes in clinical outcomes, such as fewer opioid overdoses and overdose deaths, and fewer emergency department visits. However, these important clinical outcomes would be difficult to attribute to any education alone as there are other concurrent efforts [31] that could also improve these outcomes including naloxone distribution [50], expansion of office-based opioid addiction treatment [51] with buprenorphine and naltrexone, and the availability of abuse-deterrent opioid formulations [52,53]. Evaluations focusing on decreasing the number of opioid prescriptions [54] are difficult to interpret as it is unclear what the correct amount of opioid prescribing should be to concurrently decrease opioid misuse while maintaining access to opioids for those who benefit.

The SCOPE of Pain evaluation has several limitations worth considering. Because our post-program assessments, with the exception of knowledge-testing questions, were self-reported by the participants there is risk of self-assessment bias and social desirability bias. To mitigate social desirability bias, participants completed their follow-up surveys anonymously to an independent evaluator. Program participants with a particular interest in the program objectives were potentially more likely to participate in the 2-month follow-up assessment. In addition, as this was a voluntary program, those that were interested in changing practice were more likely to enroll and, therefore, may have a greater change than the general population of practitioners. Therefore, there is the potential for participant self-selection bias. However, the demographics of those that completed the 2-month follow-up were similar to those that did not. The lack of a control group makes it difficult to attribute participant changes solely to SCOPE of Pain, however, many of the questions asked participants to attribute changes specifically to the program. While we found improvements in participant clinical knowledge, confidence, attitudes, and self-reported practice, we were unable by study design to detect if these improvements impacted patient care. Future research on ER/LA opioid REMS education should consider a more in-depth investigation on the impact on patients’ care [55].

There were a few areas where this model did not succeed. First, the FDA Blueprint is very comprehensive and requires up to 2–3 hours of education. Some participants, particularly for the web-based activity, started the program but did not complete it. For the live activity, participants were required to pass a post-test to be counted as a program completer. As clinicians are not accustomed to completing a post-test for live activities, some participants attended the entire meeting, but could not be counted as completers of the education because they did not take the post-test.

In summary, the ER/LA opioid REMS training SCOPE of Pain improved clinician-level safe opioid prescribing outcomes, however, its impact on mitigating opioid misuse risk and harm while maintaining access to opioids for those that are or would benefit remains an unanswered question. While education cannot be the only strategy to combat this national crisis, it can help improve clinician behaviors and be a major part of the solution.

Acknowledgment

Boston University School of Medicine partnered with the Federation of State Medical Boards and the Council of Medical Specialty Societies in the development, execution, and promotion of the SCOPE of Pain program.

References


31 Haegerich TM, Paulozzi LJ, Manns BJ, Jones CM. What we know, and don’t know, about the impact of state policy and systems-level interventions on prescription drug overdose. Drug Alcohol Depend 2014;145c:34–47.


In recent decades, the United States has seen a dramatic increase in opioid prescribing for chronic pain. That growth has been associated with increasing misuse of prescription opioids and has led to increases in deaths due to unintentional opioid overdose and in the number of people seeking treatment for opioid-misuse disorders. There's probably 100% agreement that we, as a profession and society, have become overly opioid-centric in our management of chronic pain. Far more controversial are the role of long-term opioid therapy in managing chronic pain and the best strategy for ending the epidemic of prescription-opioid misuse.

Groups lobbying against prescribing opioids for chronic pain remind us that the effectiveness of long-term opioid therapy has been inadequately studied. I believe that this is a case of absence of evidence rather than evidence of absence. As we await scientific evidence, questions remain regarding how best to address the epidemic of prescription-opioid misuse now. Groups advocating quick fixes believe that regulations that limit opioid availability are the best plan. This strategy is well intentioned and will certainly reduce opioid prescribing, but such blunt approaches will also limit access to opioids for patients who are benefiting or may potentially benefit from them.

Such an objection is not about protecting clinicians’ autonomy, but rather about protecting access to opioids for our patients who are in severe pain. These regulations will lead some clinicians to refuse to prescribe opioids even when they’re indicated, seeing it as too risky or too much work. They also create a climate of mistrust between patients and their health care teams. Clinicians are accused of both undertreating pain and overprescribing opioids, and patients with chronic pain who take opioids are viewed with suspicion. In addition, we don’t know what impact indiscriminate reductions in access to prescription opioids will have on long-term clinical outcomes.

Prescriber education is a more finely tuned approach to addressing the opioid-misuse epidemic, allowing us to individualize care on the basis of a patient’s needs after a careful benefit–risk assessment. That, after all, is the way we manage all chronic diseases. Education can empower clinicians to make appropriate, well-informed decisions about whether to initiate, continue, modify, or discontinue opioid treatment for each individual patient at each clinical encounter. Education has the potential to both reduce overpre-
scribing and ensure that patients in need retain access to opioids. In July 2012, a national voluntary prescriber-education initiative was begun. The Food and Drug Administration (FDA) approved a single shared Risk Evaluation and Mitigation Strategy (REMS) requiring manufacturers of extended-release and long-acting opioid analgesics to fund accredited education on safe opioid prescribing based on an FDA curricular blueprint. Although this program has not yet trained the targeted number of prescribers, a recent evaluation suggests that REMS education can shift clinicians’ self-reported practice toward safer, guideline-concordant care. Comprehensive training in safe opioid prescribing is needed at all stages of medical education (undergraduate, graduate, and continuing), since training in this area has historically been lacking. This education must go beyond opioid prescribing to include comprehensive, multimodal pain management, and it can be designed for the entire health care team: our nursing, pharmacy, and behavioral health colleagues have also been inadequately trained. This education can be coupled with enhanced clinical systems that support these new practices, including decision-support tools in electronic medical records.

Managing chronic pain is complex. Chronic pain is subjective and can present without objective evidence of tissue injury, which results in diagnostic uncertainties despite our most thorough assessments. Patients with chronic pain are desperately seeking immediate relief from their suffering; they tend to have unrealistic expectations regarding the potential benefits of opioids and not to fully appreciate the degree of risk conferred by escalating their own doses in a desperate (yet futile) attempt to obtain pain relief. Clinicians have limited tools at their disposal to help these patients. Our reimbursement system favors the use of medications alone, despite evidence supporting multimodal care. Clinicians often have no easy access to nonpharmacologic therapies and cannot obtain pain consultations because there are too few pain specialists offering comprehensive pain care. Moreover, whereas clinicians can use objective measures to guide their management of other chronic diseases, here they must rely solely on the patient’s (or family’s) reports of benefits (such as improved function) and harms (such as loss of control). Clinicians are thus left basing treatment decisions on a brief subjective assessment of whether there’s enough benefit to justify continued opioid therapy or enough harm to justify discontinuing it.

Many guidelines for safe opioid prescribing exist, and all include similar recommendations, including use of assessments of risk of opioid misuse, signed agreements that include informed consent, and monitoring strategies such as drug testing, pill counts, and prescription-drug-monitoring programs. But it’s also essential for safe-opioid-prescribing education to include teaching of effective communication skills. How does one explain to a patient who’s desperate for help that an opioid treatment must be discontinued despite the lack of alternative treatments? How does one deal with a new patient who is already taking high-dose opioids and insists that it’s the only treatment that helps?

It’s important for clinicians to judge the opioid treatment rather than the patient. When opioid therapy is deemed too risky or inadequately beneficial, discontinuing it means abandoning not the patient but merely an inappropriate treatment. When a clinician changes the treatment approach with a patient who tests positive for an illicit drug, that response is not about punishing the patient, but about changing the treatment plan on the basis of a new risk and addressing a newly identified problem.

When a clinician determines that discontinuing opioid treatment is appropriate, the patient may disagree and express anger. Is such frustration attributable to an appropriate desire for pain relief, inappropriate drug seeking, or a combination of the two? Though a patient-centered approach is always preferred, there are times in managing opioid therapy for patients with chronic pain when the clinician’s approach must be at odds with the patient’s request but intended to keep the patient safe. Such an approach may be perceived as paternalistic and may threaten the therapeutic alliance. Although transparent communication leading to a patient-centered approach is important, it goes only so far when a patient with chronic pain also shows signs of opioid misuse (e.g., unsanctioned dose escalation), necessitating discontinuation of opioid treatment.

Addressing the crisis of prescription-opioid misuse has become a national priority. To judge from the progress of the REMS program for extended-release and long-acting opioids, voluntary prescriber education may be insufficient to address this problem. Mandatory education may be re-
quired. If so, it will be important to link mandated education to medical licensure to avoid having clinicians opt out — since that could lead to reduced treatment access, as well as burnout among the clinicians who opt in. Alternatively and ideally, we could mandate proof of clinical competence, allowing clinicians who are already well trained to test out of an education requirement. Unfortunately, it may be impossible to measure such skill-based competence on a national scale.

I believe that the medical profession is compassionate enough and bright enough to learn how to prescribe opioids, when they are indicated, in ways that maximize benefit and minimize harm. Though managing chronic pain is complicated and time consuming and carries risk, we owe it to our patients to ensure access to comprehensive pain management, including the medically appropriate use of opioids.

Disclosure forms provided by the author are available with the full text of this article at NEJM.org.

From the Boston University School of Medicine and Boston Medical Center — both in Boston.

DOI: 10.1056/NEJMp1512932
Copyright © 2016 Massachusetts Medical Society.
SCOPE of Pain

SCOPE of Pain Publications


References


Chou R, et al. Management of Postoperative Pain: A Clinical Practice Guideline From the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of


Institute of Medicine (US) Committee on Advancing Pain Research, Care, and Education. *Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research.* Washington (DC): National Academies Press (US); 2011.


Krebs EE, Gravely A and Nugent S. Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain The SPACE Randomized Clinical Trial. *JAMA.* 2018;319(9):872-882.


